LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET Inc., a not-for-profit translational research institute, announced today that its partner, CILcare, a leading CRO specializing in hearing disorders, has promoted Dr. Wahid Awad to Chief Business Officer (CBO); and, the company further announced that Dr. Awad has been elected to its Board of Directors. Previously, Dr. Awad served as CILcare’s Director of Business Strategy and Alliances.
As Chief Business Officer, Dr. Awad will continue to lead all avenues of CILcare’s global business operations. In addition, as a member of its board of directors, he will be helping to establish long-term goals, strategies and plans for CILcare.
“Humbled and honored, I am excited to lead the business department to develop and implement strategies that enhance CILcare’s position as a world-leading and unique one-stop partner for external innovations in the field of hearing disorders,” said Dr. Awad. “I’m very passionate about being part of the effort to help pharma, biotech, medtech and academic institutes accelerate development of their potential solutions that prevent or cure hearing disorders such as hearing loss, tinnitus, otitis and ototoxicity.”
“Dr. Awad is most deserving of this expanded responsibility at CILcare,” said Michael Naimark, Director of Business Development at CBSET. “We value our partnership with CILcare and look forward to continuing to assist our sponsors in developing and testing pharmaceutical and implantable therapies related to hearing disorders.”
CILcare, with headquarters in Montpellier, France, and offices in Paris and Boston, is a CRO specializing in otology. CILcare has state-of-the-art laboratories, research experts in otology and neuroscience, as well as a global network of partners, enabling CILcare to offer fully customizable and comprehensive R&D programs including pharmacokinetics, preclinical efficacy, and GLP ototoxicology studies. Learn more about CILcare’s expert R&D services dedicated to ear disorders.
CBSET, with headquarters in Lexington, Mass., is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. Learn more about CBSET’s expert biomedical research services.